54.18% of Arecor Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo, a ready-to-use glucagon auto-injector pen that is used to treat hypoglycaemia in patients with diabetes; and specialty hospital care products. In addition, the company is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.

Today's Range

Now: GBX 128.50

125

128.80

50 Day Range

MA: GBX 142.73

128.50

160

52 Week Range

Now: GBX 128.50

125

299

Volume

247,000 shs

Average Volume

12,603 shs

Market Capitalization

£39.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

From Paradigm Press | Ad

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.